المؤلفون: Feyerabend S; Urologic Oncology, Studienpraxis Urologie, Nürtingen, Germany., Saad F; Urologic Oncology, Centre Hospitalier de L'Université de Montréal/CRCHUM, Montréal, QC, Canada., Perualila NJ; Health Economics and Market Access EMEA, Janssen, Beerse, Belgium. NPeruali@its.jnj.com., Van Sanden S; Health Economics and Market Access EMEA, Janssen, Beerse, Belgium., Diels J; Health Economics and Market Access EMEA, Janssen, Beerse, Belgium., Ito T; Health Economics and Market Access EMEA, Janssen, High Wycombe, Buckinghamshire, UK., De Porre P; Clinical Oncology, Janssen Research & Development BE, Spring House, USA., Fizazi K; Gustave Roussy, University of Paris Sud, Paris, France.

المصدر: Targeted oncology [Target Oncol] 2019 Dec; Vol. 14 (6), pp. 681-688.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Drug Substitution/*methods , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Prostatic Neoplasms, Castration-Resistant/*mortality, Abiraterone Acetate/administration & dosage ; Aged ; Aged, 80 and over ; Asia/epidemiology ; Canada/epidemiology ; Double-Blind Method ; Europe/epidemiology ; Humans ; International Agencies ; Latin America/epidemiology ; Male ; Middle Aged ; Neoplasm Metastasis ; Prednisone/administration & dosage ; Prostatic Neoplasms, Castration-Resistant/pathology ; Survival Rate ; Treatment Outcome

المؤلفون: Wallis CJD; Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute for Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada., Satkunasivam R; Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Saskin R; Institute of Clinical Evaluative Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada., Bansal S; Institute of Clinical Evaluative Sciences, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada., Kulkarni GS; Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Emmenegger U; Division of Medical Oncology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Nam RK; Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Institute for Health Policy, Management & Evaluation, University of Toronto, Toronto, Ontario, Canada. Electronic address: Robert.nam@utoronto.ca.

المصدر: Urology [Urology] 2018 Mar; Vol. 113, pp. 138-145. Date of Electronic Publication: 2017 Nov 27.

نوع المنشور: Clinical Trial, Phase IV; Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: United States NLM ID: 0366151 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-9995 (Electronic) Linking ISSN: 00904295 NLM ISO Abbreviation: Urology Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*adverse effects , Emergency Service, Hospital/*statistics & numerical data , Hospitalization/*statistics & numerical data , Prostatic Neoplasms, Castration-Resistant/*drug therapy , Prostatic Neoplasms, Castration-Resistant/*mortality, Aged ; Aged, 80 and over ; Androstenes/administration & dosage ; Androstenes/adverse effects ; Benzamides ; Canada ; Cohort Studies ; Docetaxel/administration & dosage ; Docetaxel/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Humans ; Kaplan-Meier Estimate ; Male ; Maximum Tolerated Dose ; Multivariate Analysis ; Nitriles ; Ontario ; Phenylthiohydantoin/administration & dosage ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/analogs & derivatives ; Population Surveillance ; Prognosis ; Proportional Hazards Models ; Prostatic Neoplasms, Castration-Resistant/pathology ; Retrospective Studies ; Risk Assessment ; Survival Analysis ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Treatment Outcome

المؤلفون: Basch E; Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: ebasch@med.unc.edu., Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C

المصدر: The Lancet. Oncology [Lancet Oncol] 2013 Nov; Vol. 14 (12), pp. 1193-9. Date of Electronic Publication: 2013 Sep 25.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Journal Article; Meta-Analysis; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Androstadienes/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Prednisone/*administration & dosage , Prostatic Neoplasms, Castration-Resistant/*drug therapy, Abiraterone Acetate ; Activities of Daily Living ; Australia ; Canada ; Cost of Illness ; Disease Progression ; Double-Blind Method ; Drug Administration Schedule ; Europe ; Humans ; Kaplan-Meier Estimate ; Male ; Pain/diagnosis ; Pain/etiology ; Pain/prevention & control ; Pain Measurement ; Proportional Hazards Models ; Prospective Studies ; Prostatic Neoplasms, Castration-Resistant/complications ; Prostatic Neoplasms, Castration-Resistant/pathology ; Quality of Life ; Surveys and Questionnaires ; Time Factors ; Treatment Outcome ; United States